PSK Biosciences is developing engineered exosome therapeutics designed for systemic, repeatable delivery of RNA medicines to hard-to-reach tissues, starting with the CNS.
Our platform integrates brain-targeting exosome engineering, quantitative RNA loading, functional intracellular delivery, and scalable CMC development to build programmable RNA therapeutics for serious diseases.
A diversified pipeline spanning CNS, pulmonary, and inflammatory diseases.
Two complementary platforms built on defined CMC and single-clone architecture.
Partner with us on exosome therapeutics, licensing, and CNS delivery.
Built on a single‑clone producer cell line architecture and a proprietary purification workflow, our platforms transform exosome drug development into defined therapeutic candidates.
A proprietary engineered exosome‑based RNA delivery platform designed to enable systemic, functional RNA delivery to the central nervous system and extrahepatic tissues.
A function‑defined natural exosome therapeutics platform based on MSC‑derived exosome subtyping with proprietary TFF and SEC‑based purification.
